Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Endometrial Neoplasms 10Ovarian Neoplasms 6Uterine Cervical Neoplasms 4Fallopian Tube Neoplasms 4Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Small Cell Lung Carcinoma 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Vaginal Neoplasms 1Uterine Neoplasms 1Somatostatinoma 1Sezary Syndrome 1Recurrent Uterine Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Ovarian Diseases 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

temsirolimus 1Sorafenib 1Sirolimus 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Uterine Sarcoma × temsirolimus × Gynecologic × Clear all
NCT01061606 2016-11-09

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Terminated
8 enrolled 6 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡